Skip to main content

Stephen S. Gottlieb, MD

Academic Title:

Professor

Primary Appointment:

Medicine

Location:

Paca Pratt, 7-N-135

Phone (Primary):

(410) 328-8788

Fax:

(410) 328-1048

Education and Training

  • AB, Brown University, Providence, RI
  • MD, Brown University Program in Medicine, Providence, RI
  • Internship and Residency, Internal Medicine, University of Chicago Hospital and Clinics, Chicago, IL
  • Fellowship, Cardiology, Mount Sinai Medical Center, New York, NY

Board Certification

  • Internal Medicine
  • Cardiovascular Disease
  • Advanced Heart Failure and Transplant Cardiology

 

 

Biosketch

Dr. Gottlieb’s investigations center on the physiology of congestive heart failure (CHF). This has included a particular interest in neurohormonal activation in CHF patients. Dr. Gottlieb was the United States principal investigator for MERIT, an international beta blocker survival trial in heart failure patients. He was also co-chairman of the mortality committee of BEST, a National Institutes of Health (NIH) and Veterans Affairs (VA) sponsored study of a different beta blocker. In addition, with the support of the local AHA, he is looking at the mechanism by which beta blockers may be effective. Other neurohormonal interests include investigation of vasopressin antagonists, adenosine antagonists, and endothelin antagonists.

Dr. Gottlieb is particularly interested in the interaction of heart failure and renal dysfunction, having studied the impact of various medications on renal function and the physiology of renal function in heart failure patients. Similarly, he is investigating the best ways to treat fluid overload, a common problem in patients with heart failure. He is actively involved in the investigation of left ventricular assist devices, investigational agents, and home telemonitoring in heart failure patients. In addition, he evaluates sleep abnormalities and the interaction of physiology and psychology in heart failure patients. He also works on the detection and treatmentof amyloidosis.

Research/Clinical Keywords

Cardiorenal syndrome, Cardiac Amyloidosis, Cardiomyopathy, Heart Failure

Highlighted Publications

Wawrzyniak AJ, Dilsizian V, Krantz, DS, Harris KM, Smith MF, Shankovich A, Whittaker KS, Rodriguez GA, Gottdiener J, Shuying Li S, Kop W, Gottlieb SS. High concordance between mental stress-induced and adenosine-induced myocardial ischemia assessed using SPECT in heart failure patients: Hemodynamic and biomarker correlates. J Nucl Med 2015; 56:1527-33.

Baron KB, Brown JR, Heiss BL, Marshall J, Tait N, Tkaczuk KH, Gottlieb SS. Trastuzumab-Induced Cardiomyopathy: Incidence and Associated Risk Factors in an Inner City Population.. J Card Fail. 2014; 20:555-559.

Blum Q, Gottlieb SS. The Effect of a Randomized Trial of Home Telemonitoring on Medical Costs, 30-Day Readmissions, Mortality and Health Related Quality of Life in a Cohort of Community Dwelling Heart Failure Patients.  J Card Failure. 2014;  20:513-21.

Gottlieb SS, Stebbins, A, Voors AA,  Hasselblad V, Ezekowitz JA, Califf RM, O'Connor CM, Starling RC,Hernandez AF. Effects of Nesiritide and Predictors of Urine Output in Acute Decompensated Heart Failure: Results from ASCEND-HF. J Am Coll Cardiol. 2013;62:1177.

Jaffe L, Kjekshus J, Gottlieb SS. Importance and Management of Chronic Sleep Apnea in Cardiology. Eur Ht J. 2013: 34, 809–815.

Additional Publication Citations

Endrighi R,  Waters AJ, Gottlieb SS, Bekkouche NS, Harris KM,  Wawrzyniak AJ, Kop W, Krantz DS Psychological stress and short-term hospitalizations or death in patients with heart failure.  Heart. 2016.

Palmer JB, Friedman HS, Johnson KW, Navaratnam P, Gottlieb SS. Association of Persistent and Transient Worsening Renal Function with Mortality Risk, Re-admissions Risk, Length of Stay, and Costs in Patients Hospitalized with Acute Heart Failure. ClinicoEconomics and Outcomes Research. 2015 ; 19:357-67.

Gottlieb SS, Harris K, Todd J, Estis J, Christenson RH, Torres V, Whittaker K, Rebuck H, Wawrzyniak A, Krantz DS. Prognostic significance of active and modified forms of endothelin 1 in patients with heart failure with reduced ejection fraction. Clin Biochem. 2014: 48:292-6.

Voors AA, Meyer S, Stepinska J, Gottlieb SS, HengstenbergC, Jones A, Zhang Y, Dahlke M, Navis GJ. Renal hemodynamic effects of serelaxin in patients with chronic heart failure: A randomized, placebo-controlled study,  Circulation-Heart Failure, 2014; 2014;7:986-993.

Clinical Specialty Details

  • Diagnosis and treatment of patients with chronic and acute heart failure.
  • Management of patients with cardiac amyloidosis

Awards and Affiliations

  • Fellow, American College of Cardiology
  • Fellow, American Heart Association
  • SIgma Xi
  • Phi Beta Kappa